FONT-SIZE Plus   Neg

Immunomedics Reveals Study Results For Radioimmunotherapy Of Colorectal Cancer

Biopharmaceutical company Immunomedics Ic (IMMU) Monday revealed that colorectal cancer can be safely, specifically and rapidly targeted with TF2 bispecific antibody and a radiolabeled peptide, with limited toxicity to the patient.

The company stated that TF2 is a bi-specific antibody created using the patented Dock-and-Lock conjugation technology. In addition to targeting the carcinoembryonic antigen expressed by many human cancers, TF2 has been engineered to recognize a small peptide that carries radioactivity. This allows the injection of radioactivity to be separated from the administration of the tumor-targeting bispecific antibody, a concept known as pretargeting.

The company further stated that the study results revealed that pretargeting has the potential advantage of delivering increased radiation dose levels selectively to the tumors while minimizing the body's exposure to radiation's harmful side effects.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Microsoft's (MSFT) office assistant Cortana for iOS beta has arrived, but only 2000 people will be able to test the virtual assistant. Apple confirmed that it has bought face animation software firm Faceshift, although it was tight lipped about how it intends to use the new addition. The move is speculated as a bid to expand into virtual reality. Environment ministry of South Korea Thursday ordered Volkswagen Korea to recall 125,522 diesel vehicles on determining actual emissions of nitrogen oxides. The ministry has asked the German automobile maker to pay a fine of 14.1 billion Won or $12.31 million. The company has to submit a recall plan by January 6, 2016.
comments powered by Disqus
Follow RTT